4
Brokerage firms have issued varied ratings on several companies. HSBC maintains a buy rating on Glenmark Pharma, anticipating IGI to become self-funding and highlighting key FDA clearances. CLSA has an outperform rating on Indus Tower, despite concerns about its Africa expansion and dividend payouts. Citigroup suggests a buy for M&M Finance, noting improvements in risk management.
